Concord Biotech Ltd.

₹1808.0

Concord Biotech Ltd.

₹1808.0

₹1808.0

-11.9 (-0.65%) - 10 Jul 2025 10:52 AM

About Company

Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology, supplying too many countries including regulated markets, such as the United States, Europe and Japan and India. It commanded a market share of over 20% by volume in 2022 across identified fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium and cyclosporine. In 2016, it launched its formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States.

Market Cap. ₹ 19,039 Cr.
52 Week - High/Low ₹ 2,664/1,345
P/E Ratio 51.05
P/B Ratio 12.48
Enterprise Value -
ROE % 21.63
RSI Value 36.88
EMA 50 1787.4
EMA 200 1782.24
Market Cap. ₹ 19,039 Cr.
52 Week - High/Low ₹ 2,664/1,345
P/E Ratio 51.22
P/B Ratio 12.47
Enterprise Value -
ROE % 21.88
RSI Value 36.88
EMA 50 1787.4
EMA 200 1782.24

Growth

Valuation

Calculators

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.